Home

Surgeon Observations
Product Overview
How it Works
Proposed Mechanism of Action
Pre-Clinical Findings
Case Studies
Published Clinical and Pre-Clinical Data
Surgical Techniques

  Code It Wright
  Find a Surgeon
  Prescribing Information
  WMT Home
  Contact Us
 

Pre-Clinical Findings:

Stronger, Faster, and More Dense Bone vs. Autograft.*

Stronger New Bone*


Graph
Mechanical properties at 13 and 26 weeks: The PRO-DENSE® regenerate on average demonstrated over six times the compressive strength vs. autograft at 13 weeks, and over three times greater ultimate compressive strength than normal, unoperated bone.

Faster, Denser Bone Regeneration*


Autograft ProDense
Histology at 13 weeks: The PRO-DENSE® specimen (right) demonstrated consistently denser and thicker trabeculae vs. autograft (left) at the same time point.
Basic Fuchsine and Toluidine Blue, 75x


All claims are based on a critically sized canine proximal humerus defect model.


"The regenerate is far denser and more robust than any other grafting material I have used. It appears that the resorption of the graft and subsequent bone replacement are timed just right."
Steven Gitelis, MD
Rush University - Chicago, IL

For Metaphyseal Bone

demand PRO-DENSE® Graft

*FASTER THAN AUTOGRAFT: The accelerated rate of healing of the PRO-DENSE® graft treated defects compared to those treated with autograft is principally evident by the higher density bone (i.e., 170% average increase in area fraction of new bone compared to autograft at 13 weeks) and superior average mechanical properties at 13 weeks.

*DENSER THAN AUTOGRAFT: Histomorphometry reveals that the amount of newly regenerated bone of the PRO-DENSE® injectable graft treated defects at 13 weeks demonstrated a statistically significant 170% average increase in new bone formation versus defects treated with autograft. PRO-DENSE® injectable graft new bone area fraction is on average 170% denser than autograft at 13 weeks.

*STRONGER THAN AUTOGRAFT: The newly regenerated bone in the PRO-DENSE® injectable graft treated defects exhibited a 645% average increase in compressive strength at 13 weeks versus defects treated with autograft.

*STRONGER THAN NORMAL BONE: At 13 weeks; Urban, et al... CORR, June 2007.

*All claims are based on a critically sized canine proximal humerus defect model. It is unknown how results from the canine model compare with clinical results in humans.

™Trademarks and ®Registered marks of Wright Medical Technology, Inc. may be covered by one or more of the following US Patents: 7,066,942. Additional patents pending.

 


AddThis Social Bookmark Button